Using the same stratification criteria for the patients as previously showed (AURKA), we found significant differences for AURKB (AURKB [mean value of 2-∆∆Ct ± SD]: 1.08 ± 0.02 versus 2.62 ± 0.12, p < 0.001 in healthy donors versus CML chronic phase cells; AURKB [mean value of 2-∆∆Ct ± SD]: 1.06 ± 0.14 versus 3.02 ± 0.21, p < 0.001, in healthy donors versus CML chronic accelerated/blast phase (Fig. 4B). The gene discussed is AURKB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.